Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06660420 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Dose Escalation and Expansion Study of PRAME T Cell Receptor (TCR) Engineered NK Cells in Participants With Recurrent and/or Refractory Melanoma (PRAMETIME-Mel)
A Phase 1 study of Recurrent Melanoma and Refractory Melanoma, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 39
- Enrollment target
- 1
- Study location
NCT06660420 is a Phase 1 study of Recurrent Melanoma and Refractory Melanoma that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 39 participants, below the 171-participant average among 23 other Recurrent Melanoma trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06660420, a Phase 1 study of Recurrent Melanoma and Refractory Melanoma, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 39 participants
- Enrollment target
- 1
- Study location
Study Summary
To find the highest tolerable dose and recommended dose of PRAME-TCR-NK cells that can be given to participants with recurrent and/or refractory melanoma. The safety and tolerability of PRAME-TCR-NK cells will also be studied.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
Study Locations (1)
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2025-02-25 |
| Est. Completion | 2031-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06660420
The ClinicalTrials.gov registry entry for NCT06660420 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 171-participant average among 23 other Recurrent Melanoma trials with a reported enrollment target (77% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Recurrent Melanoma appearing as the primary indexed condition, and to 2 interventions - of which Cyclophosphamide is the first listed.
NCT06660420 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT06660420 about?
NCT06660420 is a clinical study titled "Phase 1 Dose Escalation and Expansion Study of PRAME T Cell Receptor (TCR) Engineered NK Cells in Participants With Recurrent and/or Refractory Melanoma (PRAMETIME-Mel)". To find the highest tolerable dose and recommended dose of PRAME-TCR-NK cells that can be given to participants with recurrent and/or refractory melanoma. The safety and tolerability of PRAME-TCR-NK cells will also be studied.
What is the current status of trial NCT06660420?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 39 participants. The study started on 2025-02-25. Estimated completion is 2031-12-31.
What conditions does trial NCT06660420 study?
This clinical trial studies the following conditions: Recurrent Melanoma, Refractory Melanoma, Phase 1.
What interventions are being tested in trial NCT06660420?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG).
Who is sponsoring clinical trial NCT06660420?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06660420 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma
ACTIVE NOT RECRUITING · Phase 1
-
Decitabine in Treating Patients With Advanced Solid Tumors
COMPLETED · Phase 1
-
Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors
COMPLETED · Phase 1
-
Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers
COMPLETED · Phase 1
-
Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.